Wednesday , September 18 2019
Breaking News
Home / BUSINESS / EQUITIES / Alkem Laboratories gains as USFDA issues EIR for company’s St. Louis facility

Alkem Laboratories gains as USFDA issues EIR for company’s St. Louis facility

is currently trading at Rs. 1868.50, up by 20.00 points or 1.08% from its previous closing of Rs. 1848.50 on the BSE.

The scrip opened at Rs. 1850.00 and has touched a high and low of Rs. 1868.50 and Rs. 1830.95 respectively. So far 404 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 2158.25 on 12-Sep-2018 and a 52 week low of Rs. 1660.35 on 28-Jun-2019.

Last one week high and low of the scrip stood at Rs. 1868.50 and Rs. 1770.00 respectively. The current market cap of the company is Rs. 22101.59 crore.

The promoters holding in the company stood at 66.03%, while Institutions and Non-Institutions held 8.69% and 25.28% respectively.

US Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Alkem Laboratories’ manufacturing facility located at St. Louis, Fenton Logistics Park, USA which was inspected from August 16, 2019 to August 22, 2019 and where the Company received a Form 483 issued by the USFDA containing four observations.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.

Click & Download Udaipur Kiran App to read Latest News

Inline

Click & Download Udaipur Kiran App to read Latest News

Inline

Click & Download Udaipur Kiran App to read Latest News